What is OptiNose Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. OptiNose's interest expense for the
three
months ended in Mar. 2024 was $ -4.97 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.83 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. OptiNose's Operating Income for the
three
months ended in Mar. 2024 was $ -8.08 Mil. OptiNose's Interest Expense for the
three
months ended in Mar. 2024 was $ -4.97 Mil.
OptiNose did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
OptiNose Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptiNose (NAS:OPTN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
OptiNose's Interest Expense for the
three
months ended in Mar. 2024 was $-4.97 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-8.08 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $130.65 Mil.
OptiNose's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| OptiNose did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
OptiNose (OptiNose) Business Description
Traded in Other Exchanges
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Executives
| Marino Michael F Iii |
officer: Chief Legal Officer & Corp Sec |
C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
| Ramy A Mahmoud |
officer: President & COO |
1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
| Peter K Miller |
director, officer: Chief Executive Officer |
C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087 |
| Mvm Partners, Llc |
10 percent owner |
OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108 |
| Michele Janis |
officer: Acting Chief Financial Officer |
1020 STONY HILL ROAD, YARDLEY PA 19067 |
| Victor M Clavelli |
officer: Chief Commercial Officer |
1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067 |
| Paul Jr. Spence |
officer: Chief Commercial Officer |
1507 POWNAL DRIVE, YARDLEY PA 19067 |
| Anthony J Krick |
officer: Chief Accounting Officer |
1020 STONY HILL ROAD, YARDLEY PA 19067 |
| R John Fletcher |
director |
C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
| Kyle Dempsey |
director |
OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108 |
| Eric Bednarski |
director |
OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108 |
| Partners Llp Mvm |
10 percent owner |
30 ST. GEORGE STREET, LONDON X0 W1S SFH |
| Keith A. Goldan |
officer: Chief Financial Officer |
227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428 |
| Joseph C Scodari |
director |
JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
| Tomas J. Heyman |
director |
C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
OptiNose (OptiNose) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OPTN has been successfully added to your 